Breaking Finance News

Simulations Plus, Inc. (NASDAQ:SLP) has been upgraded to Hold in a report by Zacks Investment Research today.

Yesterday Simulations Plus, Inc. (NASDAQ:SLP) traded -0.83% lower at $8.65. The company’s 50-day moving average is $8.65 and its 200-day moving average is $8.22. The last stock close price is up 2.26% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 28,798 shares of the stock were exchanged, down from an average trading volume of 29,598

Zacks Investment Research has upgraded Simulations Plus, Inc. (NASDAQ:SLP) to Hold in a report released on 10/05/2016.

See Chart Below

Simulations Plus, Inc. (NASDAQ:SLP)

Simulations Plus, Inc. has a 52 week low of $6.74 and a 52 week high of $11.89 with a P/E ratio of 31.15 The company’s market cap is currently $0.

More About Simulations Plus, Inc. (NASDAQ:SLP)

Simulations Plus, Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *